Director Julie L. Bushman filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, along with a new stock option grant on the same date.

Key Highlights

  • Share acquisition: Julie L. Bushman acquired 2,750 shares of common stock on October 29, 2026, at a price of $0, under transaction code A.
  • Post-transaction holdings: Following the transaction, Bushman beneficially owns 11,525 shares of common stock directly.
  • New stock option granted: Bushman received stock options to purchase 3,777 shares of common stock at an exercise price of $60.96, exercisable from October 29, 2026, and expiring October 30, 2035.
  • Total options held: Bushman holds seven tranches of stock options covering a combined 25,689 shares of common stock, with exercise prices ranging from $60.96 to $128.81.
  • Filing party: The form was signed by Andrew Nick as Attorney-in-Fact for Julie Bushman pursuant to a previously filed Power of Attorney.

Bio-Techne Director Bushman's October 2026 Equity Award Details

According to the filing, Julie L. Bushman, a director of BIO-TECHNE Corp (NASDAQ:TECH), acquired 2,750 shares of common stock on October 29, 2026, at a price of $0, bringing her direct beneficial ownership of common stock to 11,525 shares. The transaction was recorded under code A, indicating an acquisition.

The filing also discloses that on October 29, 2026, Bushman received a new grant of stock options to purchase 3,777 shares of common stock at an exercise price of $60.96 per share. These options become exercisable on October 29, 2026, and expire on October 30, 2035. All options are held directly.

In addition to the newly granted options, the filing reports six pre-existing stock option tranches held by Bushman. These carry exercise prices of $69.72, $63.92, $128.81, $73.94, $61.51, and $68.37, covering 1,444, 6,028, 2,532, 3,460, 3,937, and 3,511 shares of common stock, respectively, with expiration dates ranging from July 31, 2030, through October 24, 2034. All reported options are directly held and represent rights to purchase common stock of BIO-TECHNE Corp.

What Was Disclosed

The Form 4 filed November 2, 2026, covers Director Julie L. Bushman's acquisition of 2,750 common shares at $0 and a new stock option grant for 3,777 shares at $60.96, with resulting direct ownership of 11,525 common shares and 25,689 total option shares across seven tranches.